Sabrina Browning, MD
Hematology · North Haven, CTNPI 1871938886
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by Amgen at 42.9% of the total. Reporting peaked in 2020 at $271 and has fallen 54.7% since, to $123 in 2024. That places this record below the midpoint for hematology clinicians in CT, where the typical reported total is $975.
Across 7 payments — averaging $90.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$272
- Sanofi$209
- AstraZeneca$99
- Johnson & Johnson$55
Across 80 payments — averaging $7141.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$554K
- AbbVie$17K
What the payments were for
- Food & beverage$26342%
- Education$37158%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $272 |
| Sanofi | 2 | $209 |
| AstraZeneca | 1 | $99 |
| Johnson & Johnson | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SARCLISA$141
How this compares
$634 in reported general payments places this provider in the 45th percentile of 24 hematology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 24 | $379,490 |
| PomalystPomalidomide | 17 | $372,404 |
| Acyclovir | 22 | $349 |
Paid to pharmacies, not to this prescriber.
Other hematology in North Haven
- George GoshuaNorth Haven$4K
- Thomas DuffyNew Haven$298K
- Layla van DorenNew Haven$142K
- Nikolai PodoltsevNew Haven$123K
- Thomas PrebetNew Haven$42K
- Francesca MontanariGreenwich$14K
- Natalia NeparidzeNew Haven$13K
- Anish ShardaNew Haven$10K
- Dennis SlaterNorwich$8K
- Lohith GowdaNew Haven$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.